King Wealth boosted its position in Johnson & Johnson (NYSE:JNJ) by 1.3% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 19,974 shares of the company’s stock after purchasing an additional 248 shares during the quarter. Johnson & Johnson comprises about 1.1% of King Wealth’s holdings, making the stock its 21st largest position. King Wealth’s holdings in Johnson & Johnson were worth $2,619,000 at the end of the most recent reporting period.
Several other institutional investors have also recently added to or reduced their stakes in the business. Austin Private Wealth LLC increased its position in shares of Johnson & Johnson by 2.5% in the first quarter. Austin Private Wealth LLC now owns 2,830 shares of the company’s stock worth $371,000 after acquiring an additional 68 shares in the last quarter. Sun Life Financial INC lifted its stake in shares of Johnson & Johnson by 2.5% during the first quarter. Sun Life Financial INC now owns 2,758 shares of the company’s stock worth $362,000 after purchasing an additional 68 shares in the last quarter. Dumont & Blake Investment Advisors LLC grew its stake in shares of Johnson & Johnson by 0.3% in the fourth quarter. Dumont & Blake Investment Advisors LLC now owns 20,796 shares of the company’s stock valued at $3,033,000 after buying an additional 71 shares in the last quarter. DE Burlo Group Inc. raised its holdings in shares of Johnson & Johnson by 3.9% during the 4th quarter. DE Burlo Group Inc. now owns 1,871 shares of the company’s stock valued at $273,000 after buying an additional 71 shares during the period. Finally, Modus Advisors LLC lifted its position in Johnson & Johnson by 2.0% during the 1st quarter. Modus Advisors LLC now owns 3,666 shares of the company’s stock worth $481,000 after acquiring an additional 73 shares in the last quarter. 68.51% of the stock is currently owned by institutional investors.
A number of research firms have recently commented on JNJ. Argus reissued a “buy” rating and set a $155.00 target price (down from $165.00) on shares of Johnson & Johnson in a research report on Friday, March 27th. Cantor Fitzgerald reiterated a “buy” rating and set a $168.00 target price on shares of Johnson & Johnson in a research note on Tuesday, April 28th. Raymond James lifted their price target on shares of Johnson & Johnson from $153.00 to $157.00 and gave the stock an “outperform” rating in a research note on Wednesday, April 15th. Morgan Stanley upped their price target on shares of Johnson & Johnson from $160.00 to $170.00 and gave the company an “overweight” rating in a report on Wednesday, April 29th. Finally, SVB Leerink decreased their price objective on shares of Johnson & Johnson from $172.00 to $160.00 and set an “outperform” rating for the company in a report on Wednesday, April 8th. Four analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. The stock currently has an average rating of “Buy” and an average price target of $163.47.
In related news, Director William D. Perez acquired 500 shares of the stock in a transaction that occurred on Friday, March 13th. The stock was purchased at an average cost of $127.69 per share, for a total transaction of $63,845.00. Following the purchase, the director now directly owns 16,030 shares in the company, valued at $2,046,870.70. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 0.27% of the company’s stock.
NYSE JNJ opened at $147.30 on Friday. The company has a debt-to-equity ratio of 0.41, a quick ratio of 1.05 and a current ratio of 1.31. Johnson & Johnson has a one year low of $109.16 and a one year high of $157.00. The company has a 50-day simple moving average of $149.12 and a 200-day simple moving average of $143.34. The firm has a market capitalization of $386.57 billion, a PE ratio of 16.52, a price-to-earnings-growth ratio of 3.19 and a beta of 0.70.
Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Tuesday, April 14th. The company reported $2.30 earnings per share for the quarter, topping the consensus estimate of $2.03 by $0.27. Johnson & Johnson had a net margin of 24.47% and a return on equity of 39.71%. The firm had revenue of $20.69 billion for the quarter, compared to analyst estimates of $19.48 billion. During the same quarter in the prior year, the business earned $2.10 earnings per share. Johnson & Johnson’s quarterly revenue was up 3.3% on a year-over-year basis. Equities analysts forecast that Johnson & Johnson will post 7.68 earnings per share for the current year.
The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 9th. Investors of record on Tuesday, May 26th will be issued a $1.01 dividend. This is an increase from Johnson & Johnson’s previous quarterly dividend of $0.95. The ex-dividend date of this dividend is Friday, May 22nd. This represents a $4.04 annualized dividend and a dividend yield of 2.74%. Johnson & Johnson’s dividend payout ratio (DPR) is 46.54%.
Johnson & Johnson Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON’S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON’S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Recommended Story: Current Ratio
Receive News & Ratings for Johnson & Johnson Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Johnson & Johnson and related companies with MarketBeat.com’s FREE daily email newsletter.